Vision

2. Vision To be the leading provider of integrated solutions that advance the understanding of genetics and health.

3. History • Founded April 1998 • David Walt, Ph.D., CW Group (Larry Bock), John Stuelpnagel, D.V.M., Anthony Czarnik, Ph.D., and Mark Chee, Ph.D • SNP genotyping services in 2001 • Illumina BeadLab in 2002

4. Management JAY T. FLATLEY President & Chief Executive Officer

5. Technology

6. Portfolio

7. Focused Research Strategy

8. Discovery Strategy

9. Molecular Dx Strategy

10. High Growth Markets Business Strategy

11. High Growth Markets Projected Growth • Molecular Diagnostics – 30% • Genotyping – 20% • DNA Sequencing – 10.4% • Gene Expression – 4%

12. Business Strategy Illumina Acquisitions and Investments

13. Illumina Acquisitions and Investments Industrial Consumer deCODE Genetics Mayo Clinic Children’s Hospital of Eastern Ontario CyVera Corporation Solexa Avantome GENpathway iGenix, inc.

14. Business Strategy Expand Technologies Technology Leadership

15. Business Strategy Expand Technologies Illumina Acquisitions and Investments High Growth Markets Technology Leadership Industry standard in the genetic analysis markets!

16. Throughput High Margin Consumables Platforms Markets Production Costs Low Margin Business Model

17. Financials Valuation Market Capitalization $3.58 billlion Shares outstanding 125.09 million Price $28.70 P/E (ttm): 39.81 Revenue 2006 $184,586 2007    $366,799   2008 $573,225 2009 (Est.) $654,350 Profitability (2008) Operating Margin 14.04% Profit Margin 8.81% Balance Sheet (Q3 2009) Total Assets $1,547,716 Total Liabilities $539,596 Total Stockholder Equity $1,002,120 Cash $238,528 Current Ratio 2.5

18. Financials

19. Backup-How They Work